From the Editor

A decade after the CATIE study, the focus has shifted from effectiveness to neuroprotection

Current Psychiatry. 2015 December;14(12):19-21

References

1. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
2. Vita A, De Peri L, Deste G, et al. The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. Biol Psychiatry. 2015;78(6):403-412.
3. Wakade CG, Mahadik SP, Waller JL, et al. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res. 2002;69(1):72-79.
4. Lieberman JA, Tollefson GD, Charles C, et al; HGDH Study Group. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 2005;62(4):361-370.
5. Nasrallah HA. Impaired neuroplasticity in schizophrenia and the neuro-regenerative effects of atypical antipsychotics. Medscape Psychiatry. http://www.medscape.org/viewarticle/569521. Published January 31, 2008. Accessed November 10, 2015.
6. Nasrallah HA. Haloperidol clearly is neurotoxic. Should it be banned? Current Psychiatry. 2012;12(7):7-8.
7. Nandra KS, Agius M. The differences between typical and atypical antipsychotics: the effects on neurogenesis. Psychiatr Danub. 2012;24(suppl 1):S95-S99.
8. Nasrallah HA, Hopkins T, Pixley SK, et al. Differential effects of antipsychotic and antidepressant drugs on neurogenic region in rats. Brain Res. 2010;354:23-29.
9. Pillai A, Tery AV, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BNDF levels in rat striatum and hippocampus. Schizophr Res. 2006;82(1):95-106.
10. Buckley PF, Pillai A, Evans D, et al. Brain derived neurotropic factor in first-episode psychosis. Schizophr Res. 2007;91(1-3):1-5.
11. Martin MV, Mimics K, Nisenbaum LK, et al. Olanzapine reversed brain gene expression changes induced by phencyclidines treatment in non-human primates. Mol Neuropsychiatry. 2015;1(2):82-93.
12. Yan BC, Park JH, Ahn JH, et al. Neuroprotection of posttreatment with risperidone, an atypical antipsychotic drug, in rat and gerbil models of ischemic stroke and the maintenance of antioxidants in a gerbil model of ischemic stroke. J Neurosci Res. 2014;92(6):795-807.
13. Yulug B, Yildiz A, Güzel O, et al. Risperidone attenuates brain damage after focal cerebral ischemia in vivo. Brain Res Bull. 2006;69(6):656-659.
14. Yulug B, Yildiz A, Hüdaoglu O, et al. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain Res Bull. 2006;71(1-3):296-300.
15. Elsworth JD, Morrow BA. Hajszan T, et al. Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine. Neuropsychopharmacology. 2001;36(10):2054-2061.
16. Seki Y, Kato TA, Monji A, et al. Pretreatment of aripiprazole and minocycline, but not haloperidol, suppresses oligodendrocyte damage from interferon-y-stimulated microglia in co-culture model. Schizophr Res. 2013;151(1-3):20-28.
17. Bian Q, Kato T, Monji A, et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):42-48.
18. Wang HD, Deutch AY. Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology. 2008;33(6):1276-1286.
19. Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alternations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663-671.
20. Nasrallah HA. Beyond dopamine: The ‘other’ effects of antipsychotics. Current Psychiatry. 2013;12(6):8-9.
21. Yang MC, Lung FW. Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology (Berl). 2011;217(3):397-410.
22. Peng L, Zhu D, Feng X, et al. Paliperidone protects prefrontal cortical neurons from damages caused by MK-801 via Akt1/GSK3β _signaling pathway. Schizophr Res. 2013;147(1):14-23.23.
Stojkovic´ T, Radonjic´ NV, Velimirovic´ M, et al. Risperidone reverses phencyclidine induced decrease in glutathione levels and alternations of antioxidant defense in rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):192-199.
24. Koprivica V, Regardie K, Wolff C, et al. Aripiprazole protects cortical neurons from glutamate toxicity. Eur J Pharmacol. 2011;651(1-3):73-76.
25. Vaidya VA, Marek GJ, Aghajanian GK, et al. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci. 1997;17(8):2785-2795.
26. Meridith GE, Switzer RC 3rd, Napier TC. Short-term, D2 receptor blockade induces synaptic degeneration, reduces levels of tyrosine hydroxylase and brain-derived neurotrophic factor, and enhances D2-mediated firing in the ventral pallidum. Brain Res. 2004;995(1):14-22.
27. Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr. 2007;12(suppl 4):1-13; quiz 14.

A decade after the CATIE study, the focus has shifted from effectiveness to neuroprotection

References

Pages

Recommended Reading